New Studies Show Paxlovid May Not Significantly Benefit Seniors
Recent studies suggest that Paxlovid, an antiviral medication used to treat COVID-19, may not significantly benefit vaccinated seniors. Research conducted in Ontario, Canada, found that among vaccinated older adults, Paxlovid did not show a statistically significant reduction in COVID-19 hospitalizations or mortality rates. This contrasts with earlier studies that demonstrated the drug’s effectiveness in unvaccinated populations.
New Studies Show Paxlovid May Not Significantly Benefit Seniors Read More »